Belatacept Dosage
This dosage information may not include all the information needed to use Belatacept safely and effectively. See additional information for Belatacept.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Rejection Prophylaxis
Initial dose: 10 mg/kg, intravenously, once daily, on day 1 (day of transplant, prior to implantation) and day 5, and at the end of weeks 2, 4, 8, and 12.
Maintenance dose: 5 mg/kg, intravenously, at the end of week 16 and every 4 weeks (plus or minus 3 days) thereafter.
Renal Dose Adjustments
Data not available.
Liver Dose Adjustments
Data not available.
Dose Adjustments
No dosage adjustment is recommended based on gender, weight, ethnicity, or geriatric status.
Precautions
Due to an increased risk of post-transplant lymphoproliferative disorder (PTLD), progressive multifocal leukoencephalopathy (PML), and serious CNS infections, administration of higher than the recommended doses or more frequent dosing of belatacept is not recommended.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available.
Other Comments
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for belatacept. It includes a Medication Guide, communication plan, elements to assure safe use, and an implementation system. Additional information is available at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.
Belatacept is to be used in combination with basiliximab induction, mycophenolate mofetil and corticosteroids.
The total infusion dose of belatacept should be based on the actual body weight of the patient at the time of transplantation and should not be modified during the course of therapy unless there is a change in body weight of greater than 10%.
The prescribed dose of belatacept must be evenly divisible by 12.5 mg in order for the dose to be prepared accurately using the reconstituted solution and the silicone free disposable syringe provided.
Belatacept must be prepared using only the silicone-free disposable syringe provided with each vial.
The manufacturer's product information should be consulted for complete reconstitution and dilution recommendations.
